Clinical Trial Update: Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating continuing abiraterone while discontinuing GnRH analogues in metastatic prostate cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)

Snippet

Sponsor: Montefiore Medical Center | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2026-01-26